Ongoing study

Official Study Title
Safety and efficacy of Anakinra treatment for patients with Persistent REspiratory symptoms post-acute COVID and Immune System activatION: the PRECISION double-blind, randomized clinical trial

Brief Description
The effect of the drug anakinra in the treatment of long-term complications after COVID-19. The PRECISION is a proof-of-concept, phase II randomized clinical trial aiming to evaluate the efficacy and safety of anakinra in patients with Post-Acute COVID Syndrome (PACS) of the pro-inflammatory respiratory phenotype. Improvement is measured by a composite endpoint, namely, the “Score of PACS progression reversal”.

Status: Recruiting
Study Type: Interventional (Clinical Trial)
Study phase: II
Study sites: 15 sites in Greece, 1 site in Germany, 6 sites in Italy, 1 site in Spain
Target of enrolment: 181 participants Identifier: NCT05926505
EudraCT number: 2023-000102-25
National Organization for Medicines Approval: IS24-23

Study Start: September 2023

Condition/Disease studied: Post-Acute COVID-19 Syndrome
Keywords: COVID-19; Post-Acute COVID-19 Syndrome; Coronavirus Infections; RNA Virus Infections; Post-Infectious Disorders; Chronic Disease; Antirheumatic Agents

Connect to the PRECISION trial portal

Available application for patients’ questionnaires and drug calendar